How does the loss of heterozygosity (LOH) of 1p or 16q affect the treatment options of stage II or III newly diagnosed Wilms Tumor?

For Wilms tumor patients with LOH at BOTH 1p and 16q, the COG has completed trials AREN0532 (included patients with stage 1/2 and LOH at both loci) and AREN0533 (included patients with stage 3/4 and LOH at both loci) and demonstrated an improved event free survival when therapy is intensified (to DD4A for stage 2, to regimen M for stage 3). Completed trials through both the COG and through SIOP have not integrated use of LOH of 1p OR 16q in risk stratification, and thus we do not know whether th...